event recurrence by diagnosing early and starting drug treatmentSince the appearance of interferon (IFN) -β-1b preparation in 2000, the IFN-β-1a preparation, fingolimod, natalizumab, glatiramer acetate (GA) as a disease modifying agent (DMD) used for relapse / 5 agents have been used. Apart from Finigolodo, which was released in Japan in the first year since the birth of international brains, "There are long-term experience in Europe and the United States, and we have all the data that can be referred to safety", Mr. Kira. According to Mr. Kira, IFN - β and GA are mild in efficacy but no serious side effects have been reported, as drug selection is considered as a first - line drug Easy to use drugs. On the other hand, natalizumab in which the risk of progressive multifocal leukoencephalopathy (PML) is reported, and finrimod without data accumulation for long-term safety are first choices unless it is a rapidly progressive fulminant case It is said that it will not be a medicine. Regarding the dosage form, the oral drug is only fingolimod, natalizumab is intravenous drip infusion, the first-line drug IFN-β2 agent and GA are both self-injecting drugs.
However, Mr. Kira said that less than 50% of MS patients do drug therapy in Japan where five drugs are available. One of the reasons is that it is self injection. GA is injected daily, IFN-β is administered every other day or once a week, but the injection site response becomes a problem with frequent injections, and influenza-like symptoms also lower the patient's QOL in IFN-β. Compared to Europe and the United States, MS patients in Japan are often mild cases, but even though we know the significance of early treatment initiation, it was actually difficult to use these drugs from the beginning.
The long-awaited "easy-to-use" "less burden" therapeutic drug
Even if there are few symptoms in mild case, MS patient repeats weak recurrence and brain atrophy progresses. Because it is ill in juvenile and suffering from life-threatening, it is difficult to acquire school enrollment/qualification, "difficult to find employment", "loss of opportunity for asset formation", "loss of opportunity for marriage / childbirth", "difficulty in child rearing" There are also difficulties. Therefore, it is easy to use oral medicine from the beginning, first-choice medicine that has less physical burden and can continue to be used has long been awaited.
Tefidela is an oral medicine approved in the United States in 2013 and Europe in 2014 and used in more than 21 million people worldwide. It has anti-inflammatory action of converting the balance of inflammatory type Th1/Th17 to anti-inflammatory type of Th2, neuroprotective action from nerve degenerating stimulus and oxidative stress, and in the international joint clinical trial, new gadolinium (Gd) contrasting lesion Decreased by 84% (p <0.0001) compared with the placebo group, the annual relapse rate for 2 years decreased by 49% (p <0.0001), the number of new and expanded T2 lesions decreased by 78% (P <0.0001). In the international joint study, adverse events were observed in 96 patients (86%) among 111 patients who received this drug, the main adverse events were flushes in 24 cases (22%), diarrhea and nausea in 11 cases (10 It was said that it was%).
Mr. Kira said that "Tecfidela is an easy-to-use oral medicine from the beginning, can improve medication adherence and impro |
